Estrogen receptor α (ERα) is a key regulator of breast growth and breast cancer development.
Introduction
Complementary to viewing cancer as a genetic disease, cancer can be considered a metabolic disease (1, 2) . Altered metabolism in cancer directs enhanced nutrient acquisition and facilitates assimilation of carbon into macromolecules such as lipids, proteins and nucleic acids. The net effect of these activities is to support cell growth and proliferation (3) (4) (5) (6) .
17β-estradiol (E2) and its receptor estrogen receptor α (ERα) have been implicated in promoting proliferation, survival, and migration of breast cancer cells through multiple mechanisms thereby contributing to tumor growth and progression (7, 8) . Individuals with ERα positive (ERα+) breast cancer as determined by immunohistochemistry (IHC), accounts for approximately 70% of breast cancer patients. Comparative metabolomics profiling of ERα+ and ERα negative (ERα-) breast cancer indicated clear metabolic differences correlated to hormone receptor status, including differences in glutamine and beta-alanine metabolism, as well as phospholipid metabolism (9) (10) (11) . Furthermore, estrogen stimulation enhanced the rate of glucose consumption, lactate production (aerobic glycolysis), and glutamate synthesis, and decreased the level of phosphocholine (PCho) in breast cancer cell lines (12-14).
Choline (Cho) is an essential nutrient that is necessary for cell membrane synthesis and functions as an important methyl donor (15, 16) . Routing of Cho through its various metabolic pathways is cell and tissue specific (17) . Following uptake of Cho, the intracellular metabolism of Cho is partitioned along two major pathways: (a) converted to PCho for the synthesis of phosphatidylcholine (PtdCho), a major constituent of cell membranes; or (b) oxidation to produce the methyl donor betaine (16) . Abnormally high synthesis of PtdCho via the cytidine diphosphate-choline (CDP-Cho) pathway, where CTP:phosphocholine cytidylyltransferase (CCT) has been identified as the rate-limiting enzyme, is generally recognized as a metabolic hallmark of cancer (18, 19) . PtdCho can also be synthesized through 5 methylation of phosphatidylethanolamine (PE) by phosphatidylethanolamine Nmethyltransferase (PEMT) (20) . The PEMT gene has been shown to be induced by estrogen in hepatocytes (20) .
Increased levels of PCho and total Cho-containing metabolites have been identified as markers for breast cancer (21) . Furthermore, increased synthesis of PtdCho is one of the earliest metabolic events associated with the initial stimulation of cell growth and proliferation by tumor promoters in normal cells (22) (23) (24) . PtdCho has also been found to be increased in breast cancer cells by tumor promoter (25). Consistently, human breast cancer cells have been shown to have higher levels of PtdCho than normal human mammary epithelial cells (26) . Underlying mechanisms and potential drug targets in abnormal Cho phospholipid metabolism have been widely investigated in different cancers as reviewed in (19) . Overall, the regulation of Cho phospholipid metabolism in breast cancer cells has been shown to depend on breast cancer subtype with respect to gene expression profiles and metabolic fingerprints (27) .
Several studies have provided important insights into global estrogen regulated gene networks based on profiling ERα binding regions and estrogen regulated expression (28-33). To extend global estrogen regulated networks to effects on breast cancer metabolism, we report a comprehensive analysis of estrogen regulated metabolic pathways in two breast cancer cell lines. We integrate cistrome, transcriptome and metabolome data to identify metabolic pathways regulated by estrogen signaling via ERα. We focus on effects conserved between two ERα+ breast cancer cell lines with the aim to identify general effectors of metabolic signaling rather than cell type specific effects.
Materials and Methods
Additional and detailed methods are included in the supplementary materials and methods. 
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) or qPCR
ChIP was performed as previously described (34) .
Gene expression microarray analysis
The gene expression data for MCF7 cells has been previously published (33) . For T47D cells, Human Gene 2.1 ST Arrays were used for analysis of global gene expression profiling. The microarray data are deposited in GEO (accession number GSE36683 and GSE74034 for MCF7 and T47D cells, respectively).
GO analysis and identification of enriched pathways were performed using the WEB-based GEne SeT AnaLysis Toolkit.
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NMR spectroscopy
Water soluble metabolites were extracted using ethanol. NMR spectra were recorded on a Bruker Avance III 600 MHz spectrometer. A multivariate comparison of metabolic profiles from estrogen-stimulated and control cells was performed using partial least squares discriminant analysis (PLSDA) on Pareto-scaled NMR spectra using PLS_Toolbox v7. 5 
Zebrafish metastatic model
TMX-sensitive MCF7 cells and TMX-resistant LCC2 cells were used. The zebrafish metastatic model was established as previously described (35) .
Results
A core set of direct ERα-regulated genes in ERα+ breast cancer cells
To identify a core set of direct ERα-regulated genes, we combined genome-wide ERα binding profiles with detailed transcript profiling for the two breast cancer cell lines, MCF7 and T47D. (Fig. 1A) . General properties of the identified ERα binding regions, such as peak distribution and enriched motifs, are consistent with previously published studies ( Supplementary Fig. 1A-C) . Overlaying the MCF7 and T47D cistromes revealed 6480 shared binding regions, corresponding to 36% and 51% of the MCF7 and T47D cistromes, respectively ( Fig. 1A and 1B) . The shared binding regions overlapped with published ERα cistromes for breast cancer cell lines (Supplementary fig. 1D ).
Global gene expression profiling revealed 2531 and 1800 estrogen regulated genes in MCF7 and T47D cells, respectively (Fig. 1C) . Overlaying the estrogen regulated MCF7 and T47D transcriptomes identified 420 common estrogen induced and 348 common estrogen repressed genes (Fig. 1C) . ERα binding was enriched in regions associated with estrogen induced genes as compared to repressed genes for both MCF7 and T47D cells (Fig. 1D) . To further identify a core set of direct ERα target genes common to MCF7 and T47D cells, we combined well-established direct ERα target genes were included in the identified core set, such as trefoil factor 1 (TFF1), growth regulation by estrogen in breast cancer 1 (GREB1), and progesterone receptor (PR). A majority (71%) of the core set of direct ERα target genes were induced by E2 treatment (Fig. 1E ).
Gene ontology (GO) pathway analysis for the core set of direct ERα target genes showed significant enrichment of cancer pathways. Interestingly, metabolic pathways were also enriched ( Fig. 1F ). Overlaying the identified core set of direct ERα target genes with 1620 metabolic enzymes extracted from the KEGG database revealed that 19 genes encoding metabolic enzymes were direct ERα target genes in the two investigated cell lines, including 9 estrogen upregulation of ADCY9, B4GALT1, CA12, CHPT1, CHSY1, ENTNK2, FHL2, ITPK1, MBOAT1, PISD, PTGES, and SLC27A2 and estrogen downregulation of ABCC5, ABCG1, ACSL1, CYP1A1, CYP1A2, RXRA, and ST3GAL1 (Fig. 1G ).
Estrogen signaling leads to global metabolic reprogramming in breast cancer cells
We determined the effect of estrogen signaling on levels of intracellular and extracellular metabolites using proton nuclear magnetic resonance ( 1 H NMR). However, we also observed differential effects of estrogen on Cho-containing metabolites between these two cell lines, with glycerophosphocholine (GPC) levels being reduced in MCF7 cells and Cho levels increased in T47D cells (Supplementary Fig. 2A and 2B).
Analysis of extracellular metabolites revealed that upon estrogen treatment, MCF7 cells consumed more glucose and produced more lactate ( Fig. 2C and 2D ), leading to a higher lactate/glucose ratio (Fig. 2E) . Surprisingly, T47D cells consumed significantly higher amounts of glucose than MCF7 cells regardless of estrogen treatment ( Fig. 2C where the extracellular concentration of glucose is much lower for T47D cells compared to MCF7 cells).
Similarly as observed for MCF7 cells, estrogen stimulation enhanced glucose consumption and the lactate/glucose ratio for T47D cells ( Fig. 2C and 2E ), supporting elevated aerobic glycolysis upon activation of estrogen signaling in ERα+ breast cancer cells. However, estrogen treatment did not affect lactate levels in T47D cells (Fig. 2D ).
Estrogen signaling regulates transcripts and metabolites of the Cho metabolic pathway in breast cancer cells
The glycerophospholipid pathway which includes the Cho metabolic pathway was enriched for direct ERα target genes common to MCF7 and T47D cells (Fig. 1F) . Specifically, of the 119 genes involved in the KEGG Homo sapiens glycerophospholipid pathway hsa: 00564 (27), 26 and 10 were regulated by estrogen in MCF7 and T47D cells, respectively (Fig. 3A) .
Regulation of a subset of these genes was confirmed using qPCR (Fig. 3B) .
Additionally, metabolic profiling confirmed alterations in Cho metabolism in response to estrogen signaling for these two cell lines (Fig. 2B, Supplementary Fig. 2A and 2B ). Figure   3C shows changes in the levels of metabolites in the Cho metabolic pathway upon estrogen stimulation. NMR metabolic profiling of polar extracts is not suitable for determination of the lipid soluble metabolite PtdCho, and CDP-Cho is present in too low concentration for detection by NMR. To obtain a more complete overview of the effects of estrogen on Cho 11 metabolism, we assayed these metabolites by alternative assays, i.e. PtdCho levels by PtdCho Assay Kit and CDP-Cho levels by LC-MS. We observed increased levels of CDP-Cho in MCF7 cells after estrogen stimulation, while no difference in T47D cells was observed (Fig.   3C ). Interestingly, PtdCho levels were significantly increased 24 h after estrogen treatment in both MCF7 and T47D cells (Fig. 3D) . Furthermore, CHPT1, the direct upstream enzyme to catalyze PtdCho synthesis, was identified as the only direct ERα target gene in the Cho pathway, which was upregulated upon estrogen stimulation in both analyzed cells (Fig. 3A, 3E and 3F).
All estrogen regulated genes and metabolites in the Cho metabolic pathway are indicated in Figure 3G . The expression of transmembrane Cho transporters, solute carrier family 44, members 1 and 2 (SLC44A1, SLC44A2) encoding CTL1 and CTL2, was reduced significantly after estrogen stimulation in MCF7 cells (Fig. 3B ). The expression of CHKB and CHKA, which are responsible for Cho phosphorylation, was reduced by estrogen in MCF7 and T47D cells, respectively (Fig. 3B) . Consistently, PCho levels were decreased in both cell lines (Supplementary table 4) . Phospholipase A2, group VI (PLA2G6) was downregulated upon estrogen stimulation in MCF7 cells (Fig. 3B) , which may result in decreased levels of its downstream product GPC, which is consistent with reduced GPC levels in this cell line in response to estrogen stimulation. The expression of PLCD1 and PLCE1 was significantly decreased in estrogen treated MCF7 cells (Fig. 3B ). Another isoform of PLC, PLCB3, was downregulated by estrogen in T47D cells (Fig. 3B) . Down-regulation of PLCs may result in less PCho production, consistent with what was observed for MCF7 and T47D cells (Supplementary table 4 ). However, it should be noted that changes in gene expression do not necessarily translate into changes in enzyme activity and metabolite concentrations.
GPC is formed by the deacylation of PtdCho. Elevated PCho/GPC ratio has been observed in breast cancer cell lines compared to normal breast epithelial cells (36) . Furthermore, it has been proposed that this ratio can predict on breast cancer aggressiveness (37,38). Our results
show that estrogen stimulation increased the PCho/GPC ratio in MCF7 cells (Supplementary   table 4) . On the contrary, in T47D cells, the PCho/GPC ratio was reduced (Supplementary   table 4) .
Estrogen stimulation increases the activity of CCTα
CCTα is a key enzyme in the CDP-choline pathway for de novo PtdCho biosynthesis. This enzyme is inactivated when it is phosphorylated, and activated by a phosphatase which allows it to translocate to membranes (39) . To understand whether E2 regulates CCTα activity, we investigated the cellular distribution of CCTα. Notably, CCTα expression was detected in cytosol, membrane and nuclear fractions (Fig. 4A) . Interestingly, the level of CCTα was significantly decreased in the cytosol fraction, while it was increased in the membrane upon E2 stimulation in MCF7 and T47D cells (Fig. 4A) , suggesting that CCTα was recruited to the membrane and activated in response to E2 treatment. However, no change of CCTα was observed in nuclear fraction upon E2 treatment (Fig. 4A) . The separation of cytosol, membrane and nuclear proteins was confirmed by assaying the cytosolic proteins GAPDH and α-tubulin, the membrane associated proteins cadherin and TIM 23, and nuclear associated protein lamin (Fig. 4A) .
CHPT1 is critical for estrogen induced PtdCho synthesis
E2 stimulation led to upregulation of both CHPT1 and its direct downstream metabolite PtdCho ( Fig. 3B and 3D) . To confirm the role of CHPT1 in estrogen regulation of PtdCho, we assayed PtdCho levels upon CHPT1 depletion with and without E2 treatment in MCF7 and T47D cells. Efficient knockdown of CHPT1 was confirmed by qRT-PCR and western blot analysis (Fig. 4B) . Importantly, PtdCho levels decreased significantly after CHPT1 knockdown, supporting a critical role of CHPT1 in regulating PtdCho synthesis (Fig. 4C ).
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Furthermore, the effect of estrogen in promoting PtdCho synthesis was significantly reduced after CHPT1 knockdown (Fig. 4C) , suggesting that estrogen induced PtdCho synthesis is dependent on CHPT1 expression. To further explore how metabolites of the Cho metabolic pathway are affected upon CHPT1 depletion, we determined levels of Cho-containing metabolites by 1 H-NMR in MCF7 cells upon CHPT1 depletion compared to control in the presence and absence of E2. As shown in Fig. 4D , CHPT1 depletion increased the levels of Cho, suggesting that CHPT1 contributes significantly to metabolic turnover in the Cho pathway in MCF7 cells. Interestingly, a significant reduction of the PCho/GPC ratio was observed upon CHPT1 depletion, and additionally, increase of the PCho/GPC ratio by E2 was abolished by CHPT1 depletion (Fig. 4E ). This indicates that CHPT1 is a critical regulator of the PCho/GPC ratio, which previously has been suggested as a potential prognostic biomarker in breast cancer (40) . To understand whether the PEMT pathway contributes to the increase in PtdCho levels, we assayed PEMT mRNA levels in response to E2 stimulation. However, the expression of PEMT was not induced by estrogen in the assayed breast cancer cell lines (Supplementary table 5 ).
CHPT1 increases anchorage-independent growth and proliferation of breast cancer cells
To further uncover the role of CHPT1 in ERα positive breast cancer cells, we examined anchorage-independent growth and proliferation after CHPT1 knockdown. As shown in Figures 5A and 5B, CHPT1 knockdown reduced the number of colonies of MCF7 and T47D cells in soft agar compared to the control. Furthermore, we observed that knockdown of CHPT1 decreased cell proliferation in both cell lines (Fig. 5C ). 14 To confirm CHPT1 dysregulation in breast cancer, we determined CHPT1 protein levels in tumor tissue and adjacent normal breast tissue by IHC, using tissue microarrays (TMAs) for which data was provided regarding tumor nodes and metastasis (TNM), clinical stage and pathology grade, and IHC-staining for HER-2, ER and PR. Consistent with published data by
CHPT1 is overexpressed in breast cancer
The Human Protein Atlas (http://www.proteinatlas.org/ENSG00000111666-CHPT1/tissue),
we observed that almost all CHPT1 staining was localized to the cytoplasm (Fig. 5D ).
Although cytoplasmic staining was observed in both normal and cancerous tissue, staining was stronger for tumor tissues ( Fig. 5D and 5E 
Knockdown of CHPT1 inhibits early stage of metastasis of TMX-resistant breast cancer cells in vivo
To increase knowledge about the role of CHPT1 in invasion of TMX-resistant breast cancer cells, we performed transwell cell invasion assays for both TMX-sensitive MCF7 cells and TMX-resistant LCC2 cells upon CHPT1 knockdown (Fig. 6A) . The invasion assay showed that LCC2 cells were more invasive than MCF7 cells (Fig. 6B) . Knockdown of CHPT1 markedly inhibited invasion of both MCF7 and LCC2 cells (Fig. 6B) . To further study the role of CHPT1 in regulating early stage of metastasis of TMX-resistant breast cancer cells in vivo, we used a zebrafish tumor model (36) . Tumor-implanted fish embryos were scored for the dissemination of tumor cells at day 4 after injection. Control-siRNA-treated LCC2 cells disseminated more widespread in the fish body as compared to control-siRNA-treated MCF7
cells. Reduced dissemination of tumor cells was observed for both MCF7 and LCC2 cells after CHPT1 knockdown (Fig. 6C) . Notably, a stronger suppression of invasion and metastasis following CHPT1 depletion was found in LCC2 cells compared to MCF7 cells (Fig. 6D ).
Discussion
Here confluence, serum deprivation, and acidic extracellular pH could all affect metabolite levels (43) . Furthermore, we have previously demonstrated that distinct metabolic profiles are associated with differences in gene expression for different subtypes of breast cancer (27) .
However, importantly, estrogen regulated metabolites for the two breast cancer cell lines were related to four metabolic pathways, aerobic glycolysis, nucleotide and amino acid synthesis, and glycerophospholipid metabolism, suggesting that ERα activation may increase the production of metabolic intermediates for the synthesis of proteins, nucleic acids and lipids to support the rapid proliferation of cancer cells.
Alterations in membrane phospholipids are associated with malignant transformation (36), tumorigenicity (19) , and metastasis (44) . Interestingly, glycerophospholipid metabolism was one of the enriched pathways of direct ERα target genes, and additionally our metabolic profiling showed alterations in Cho-metabolite levels in response to estrogen signaling. We report that E2 decreased PCho levels and increased PtdCho levels in both MCF7 and T47D cells (Supplementary table 4 and Fig. 3D ). E2 suppression of PCho in T47D cells is consistent with a previous report (12). Metabolite levels are regulated by rate of synthesis and consumption of the metabolite. Reduced PCho could be attributed to decreased CHK expression ( Fig. 3B and Supplementary table 4), but also to increased CCTα activity leading to higher consumption of PCho for CDP-Cho synthesis ( Fig. 3C and Fig. 4A ). Moreover, down-regulation of PLC could also result in less PCho production (Fig. 3B) . Furthermore, we could not exclude the possibility that PCho is dephosphorylated by phosphatases. However, it should be noted that the relationship between transcript levels and metabolite concentrations in the Cho pathway is highly complex and depends on several collateral biochemical reactions.
Furthermore, it is difficult to correlate changes in metabolic flux through the pathway to steady-state metabolite levels. The metabolic effects of estrogen stimulation can therefore not be conclusively determined from changes in gene expression.
The activity of CHPT1 is regulated by thyroid hormone (45) , and by arginosuccinate. Here we demonstrate that E2 stimulation led to upregulation of CHPT1 and increased PtdCho levels in 17 breast cancer cells (Fig. 3B and 3D) . Notably, CHPT1 depletion not only decreased PtdCho levels, but also increased Cho levels in MCF7 cells (Fig. 4C and 4D ). Accumulation of Cho may be the result of reduced flux through the pathway due to reduced CHPT1 activity. Our results suggest that CHPT1contributes to regulation of PtdCho synthesis in the context of ER signaling in breast cancer. CCT, the rate liming enzyme for PtdCho synthesis, has been reported to display increased expression in cancer (46, 47) . Interestingly, no induction of PCYT, which encodes CCT, was found upon E2 stimulation (Fig. 3G) . However, E2
stimulation increased the activity of CCTα (Fig. 4A) , which could result in sufficient substrate production for CHPT1 (CDP-Cho) to synthesize PtdCho (Fig. 3C) . Hence, our study indicates that increased CHPT1 expression and increased CCTα activity was involved in the estrogeninduced increase in PtdCho synthesis (Supplementary table 5) .
Previous studies have shown up-regulation of CHPT1 mRNA levels and activity in human breast cancer cells compared to normal mammary epithelial cells (48, 49) . Furthermore, the PCho/GPC ratio has been associated with malignant transformation (36, 50) . In agreement with this, CHPT1 knockdown reduced the PCho/GPC ratio in MCF7 cells (Fig. 4E) , and decreased anchorage-independent growth (Figs. 5A and B) and proliferation of breast cancer cells (Fig 5C) .
In conclusion, our study has uncovered that ERα activation reprograms metabolism in breast (Fig. 7) . Finally, as CHPT1 is overexpressed in breast cancer supports it is a potential drug target to be further investigated.
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